These findings suggest that targeting mutant FAT1, in combination with CPI‐613, could represent a promising new therapeutic strategy for treating HPV‐ HNSCC patients harboring FAT1 mutations. This evidence concerns the gene FAT1 and head and neck squamous cell carcinoma.